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ABSTRACT 
Objectives: To examine the association between hormone therapy (HT) and cognitive 
performance or dementia, focusing on the duration and type of treatment used, as well as the 
timing of initiation of HT in relation to the menopause.  
Methods: Women 65 years and older were recruited in France as part of the Three City Study. 
At baseline and 2 and 4 year follow-up, women were administered a short cognitive test battery 
and a clinical diagnosis of dementia was made. Detailed information was also gathered relating 
to current and past HT use. Analysis was adjusted for a number of socio-demographic, 
behavioural, physical and mental health variables, as well as Apolipoprotein ε4 (Apoe-ε4).   
Results: Among 3130 naturally postmenopausal women, current HT users performed 
significantly better than never users on verbal fluency, working memory and psychomotor speed. 
These associations varied according to the type of treatment and a longer duration of HT 
appeared to be more beneficial. However, initiation of HT close to the menopause was not 
associated with better cognition. HT did not significantly reduce dementia risk over 4 years but 
current treatment diminished the negative effect associated with Apoe-ε4.  
Conclusions: Current HT was associated with better performance in certain cognitive domains 
but these associations are dependent on the duration and type of treatment used. We found no 
evidence that HT needs to be initiated close to the menopause to have a beneficial effect on 
cognitive function in later life. Current HT may decrease the risk of dementia associated with the 
Apoe-ε4 allele.   
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INTRODUCTION 
Postmenopausal hormone therapy (HT) remains the most effective treatment for alleviating 
menopausal symptoms which affect up to 80% of women, yet its effect on cognitive ageing 
remains controversial
1, 2
. The discordance in findings across studies could relate to differences in 
study design and cognitive assessment. Compared to observational studies, randomised 
controlled trials (RCTs) are less susceptible to bias, in particular the healthy-user bias of women 
selectively taking treatment. Yet, the majority of RCTs have a shorter follow-up, and long-term 
changes in cognitive function over time may not be recorded. In addition, HT may have varying 
effects on specific cognitive functions, with evidence that it could preferentially protect verbal 
memory
3
, although other specific domains have not been extensively studied. Most studies have 
focused on dementia or global function which may have ceiling effects in non-demented people. 
The type of HT and the duration of use might also play a role in determining its effect
4
, and 
treatment may need to be administered around the menopause to have an optimal beneficial 
effect on later-life cognition
5
.  
While the role played by HT in cognitive dysfunction remains an important question to be 
addressed, it is unlikely to be answered in the near future by large-scale RCTs with long-term 
HT users. However, it is currently feasible to use existing data on hormone exposure and later-
life cognition from longitudinal population-based studies. This study aims to determine the 
association between dementia or specific areas of cognition and different characteristics of HT in 
naturally postmenopausal women.  
 
METHODS 
The Three City Study (3C) is a multi-centre longitudinal study involving the French cities 
Bordeaux, Dijon and Montpellier of community-dwelling elderly
6
. Recruitment of the study 
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cohort took place between 1999 and 2001 with eligible participants (aged over 65 years and non-
institutionalised) being randomly selected from the electoral rolls. Participants were administered 
standardised questionnaires by trained staff and underwent clinical examinations at baseline and 
each 2-year follow-up. Fasting blood samples were provided and Apoe-ε4 genotyping was also 
performed
7
. The data described here was gathered during the first 4 years of the study. 
Standard protocol approvals, registrations and patient consents 
The study protocol was approved by the Ethical Committee of the University- Hospital of 
Kremlin-Bicêtre (France). Written informed consent was obtained from all participants in the 
study. 
Cognitive function 
A battery of cognitive tests was administered by trained staff and assessed different areas of 
cognitive function (Table 1), as detailed previously
8
. All of the tests were administered at 
baseline, and wave 1 and 2 of follow-up, except the Trail Making test which was not given in 
wave 1. Consequently, analysis of these tasks involves 356 fewer participants.  
Dementia diagnosis 
A preliminary diagnosis and classification of dementia at each follow-up was made by 3C study 
clinical investigators, according to DSM-IV revised criteria
9
 and was further validated by a 
national panel of neurologists independently of the 3C investigators. The onset of dementia was 
the date of the follow-up interview when dementia was diagnosed. 
HT 
Participants recorded current and past HT use, the duration and type of treatment, and age when 
treatment was first initiated. Current treatment was validated by presentation of the prescription 
or the medication. Menopause age and type of menopause were noted.   
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Statistical Analysis 
Logistic regression models were deemed the most appropriate for our analysis, due to the 
distribution of scores on the cognitive tests. Low cognitive performance was defined as scoring 
in the lowest quintile for each cognitive test except the TMTA and TMTB, which were timed 
tasks and thus the highest quintile was considered. A substantial decline in cognitive function 
over follow-up was defined as the lowest quintile of the difference between baseline score and 
either follow-up visit, or the highest quintile for TMTA and TMTB. Multivariate models 
adjusted for age, education, centre, marital status, caffeine consumption, BMI, menopause age, 
anticholinergic medication, depressive symptoms, comorbidity, physical incapacities and Apoe-
ε4. Longitudinal models also adjusted for baseline cognitive score. Cox proportional hazards 
models with delayed entry assessed the association between HT and dementia incidence. To 
avoid the non-proportionality in dementia risk with age, the time scale was age and the time 
origin birth
10
. Interaction terms between HT and other risk factors for cognitive function or 
dementia were considered. SAS (v9.1) was used for the analyses (SAS Institute,Inc.,North 
Carolina).   
 
RESULTS 
Of the 4429 naturally postmenopausal women initially recruited into the study, women were 
excluded from this analysis if they were diagnosed with possible dementia at inclusion (n=86), or 
if they died or were lost to follow-up (n=439). Women were also omitted if they had missing 
data concerning: cognitive testing at baseline or follow-up (n=400); HT use (n=118); or one of 
the covariates (n=256). Compared to the analysed sample (n=3130), those excluded were more 
likely to be older, single, depressed, never HT users and to have a lower education level, an 
earlier menopause age, physical incapacities, comorbidity and lower scores on all cognitive tests 
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(p<0.001). Fifteen percent of the women studied reported current HT use, and a similar number 
were past users (Table 2). With the exception of the MMSE, the percentage of women who 
performed poorly on each of the cognitive tests was lowest among current HT users and highest 
amongst the never users.     
Baseline cognitive function 
In multivariate adjusted models (Table 3), current HT use was significantly associated with 
better performance on tasks of verbal fluency, visual memory and psychomotor speed, compared 
to women who had never used HT. There was no significant association between HT use and 
global cognitive function, verbal memory or executive function. There was no significant 
difference in cognitive performance between never and past HT use overall (data not shown), 
however recent past use (≤2yrs ago), was still associated with significantly better verbal fluency. 
Adjusted regression models (Table 4) further indicated that long rather than short-term HT was 
significantly associated with better performance on the Isaacs and TMTA tasks. However, this 
duration effect was not observed with visual memory. Only women initiating treatment more 
than 5yrs after the menopause had a reduced risk of poor verbal fluency compared to never HT 
users, but there was no apparent beneficial effect of later initiation with regards to visual 
memory and psychomotor speed. Transdermal estrogen preparations combined with a 
progestagen, and in particular synthetic progestin, were most significantly associated with a 
decreased risk of poor performance in the three areas of cognitive function examined.  
Change in cognitive function  
We failed to find a significant adjusted association between baseline HT use and 4-year change 
in global function (p=0.32), verbal fluency (p=0.63), visual memory (p=0.65), verbal memory 
(p=0.41) or executive function (p=0.93). However, HT use was associated with a decreased risk 
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of decline in psychomotor speed (OR=0.73, 95%CI:0.53-0.99,p=0.05). There was no difference 
in terms of the type or the timing of initiation of treatment.  
Dementia Incidence 
Over follow-up there were 79 cases of all-cause dementia and 53 were classified as Alzheimer’s 
disease (AD). Adjusted Cox models failed to find a significant association between HT use and 
the incidence of dementia or AD (Table 5). However, the risk of dementia associated with Apoe-
ε4 appeared to vary according to HT use. Apoe-ε4 was a strong risk factor for dementia 
incidence overall, and in stratified analysis increased dementia risk among never users, with a 
similar trend for past users. By contrast, there was no significant increase in dementia risk for 
women with an Apoe-ε4 allele who were current users of HT. The findings were comparable 
when we examined AD.  
 
DISCUSSION 
The effect of HT on cognitive function has been widely debated since publication of the results 
from the Women’s Health Initiative Memory Study (WHIMS). In this large RCT, non-
hysterectomized women administered conjugated equine estrogen (CEE) and 
medroxyprogesterone acetate (MPA), had a significantly increased risk of global cognitive 
decline
11
 and of all-cause dementia
12
 but not of mild cognitive impairment. Combined CEE and 
MPA also had a negative effect on verbal memory
13
. These negative results contrast with a 
number of observational studies, and our study has attempted to clarify such inconsistencies, by 
investigating different characteristics of HT and their association with a range of cognitive 
domains.  
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Our study supports the notion that HT has varying associations with different areas of cognitive 
function. We found that current HT users performed significantly better on the tasks of verbal 
fluency, visual memory and psychomotor speed, however there was no significant association 
with global function, verbal memory or executive function. Current HT was also significantly 
associated with a reduced risk of 4-year decline in psychomotor speed. By contrast, past HT was 
not significantly associated with cognitive performance except very recent past use (<2yrs) and 
verbal fluency. This suggests that any beneficial effect from current exposure is removed once 
treatment is stopped. Our findings corroborate previous meta-analyses of observational studies, 
showing that HT is associated with better functioning in certain specific domains
14, 15
, such as 
working memory
16
 and the WHIMS RCT also found a positive effect of HT using the same 
visual memory task (BVRT)
13
. However, of the previous studies which examined psychomotor 
speed, the majority found no association with HT use
13, 17
. Evidence indicates that HT may 
preferentially protect verbal performance, i.e. verbal fluency
18, 19
 or verbal memory
2
, although 
this has not been found consistently
13, 16
. Our study supports the beneficial effect of HT on verbal 
fluency, but no significant association with word recall. As we used only one measure of verbal 
memory, which is subject to ceiling effects in non-demented people, it is still possible that HT 
could be associated with other tasks assessing this same cognitive domain.  
We found that the association of HT with cognitive function varied according to the duration and 
type of treatment, which emphasizes the importance of considering characteristics of HT. The 
majority of RCTs are short and only one type of treatment is administered, so important effects 
may not have been observed. To date, few observational studies have examined whether the type 
of HT used can influence the associations found. In contrast with the WHIMS where equine 
estrogen and MPA were used, the majority of women in our study used combined transdermal 
estradiol-progestagen preparations and this treatment was associated with better verbal fluency, 
visual memory and psychomotor speed. Interestingly however, the associations with cognitive 
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function remained significant after adjustment only among women using synthetic progestin, 
most commonly 19-norprogesterone derivatives (medrogestone or promegestone). The 
demographic characteristics of women using the different HT preparations were very similar, 
with the exception that users of estrogen alone were slightly older than women reporting other 
formulations. While variability in neuroprotective effect depending on the type of progestagen is 
not surprising, previous research suggests natural progestagens may be preferred over synthetic 
ones such as MPA
20
. The effect of 19-norprogesterone derivatives has however, not been 
evaluated in epidemiological studies, although they are among the most selective agonists of the 
progesterone receptor (also referred as “pure” progestagens), notably devoid of estrogenic, 
androgenic or glucocorticoid activities in contrast with MPA 
21
.  Definite conclusions cannot be 
drawn regarding the impact of progestagens however, as the absence of significant associations 
may result from the smaller sample size and thus a difference in statistical power.   
Our finding that women reporting long-term rather than short-term treatment, performed 
significantly better on the tasks of verbal fluency and psychomotor speed, is in accordance with 
other studies reporting beneficial effects from increasing HT duration
17, 19
. Thus treatment may 
need to be administered for a sufficient length of time before any positive effects are observed. 
This could help explain the absence of significant effects in some RCTs, due to the shorter 
treatment period. Likewise, in the WHIMS, the positive and negative effects of HT on visual and 
verbal memory respectively, were only evident after long-term treatment. 
As one of the few studies to directly examine the “critical window” hypothesis, we found no 
evidence to suggest that HT needs to be initiated close to the menopause to have a beneficial 
effect on later-life cognitive function. In fact in terms of verbal fluency, only women initiating 
treatment >5yrs after the menopause performed significantly better than women who had never 
used HT. The critical window hypothesis was thought to partially explain why positive 
associations between HT and cognition have been found more frequently among peri- or early 
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postmenopausal women, compared to older populations
2, 22
. However, only a couple of small 
studies have directly tested this hypothesis
23, 24
. Among 343 naturally postmenopausal women, 
those receiving 2-3yrs of treatment in the early postmenopausal had a decreased risk of overall 
cognitive impairment
23
. Similar results were also seen for women who were either current or 
long-term HT users, although with half the sample size, this did not reach significance. Thus this 
study showed that treatment in the early postmenopause can have long-lasting effects on 
cognitive function, but later initiation may also be beneficial
23
. In the REMEMBER pilot study 
25
 
of 428 women aged over 60yrs, those who commenced HT before 56yrs had significantly better 
global function, compared with women initiating HT later, as well as better performance on the 
TMTA, a finding that was not supported by our data. However, with respect to the other 
cognitive domains examined, no significant difference was found between early and late 
initiators, including the positive association between HT and verbal fluency. In this study age at 
HT initiation was examined, rather than timing in relation to the menopause, and the authors did 
not differentiate current from past HT users or the duration of HT use. They also included both 
natural and surgically menopausal women, who may respond differently to HT in terms of 
cognitive outcomes
5, 26
. Hence, the “critical window”  hypothesis is still awaiting definitive 
proof. On the other hand, additional experimental and clinical imaging observations suggest that 
even a delayed initiation of HT may still have beneficial effects on particular brain functions; the 
longer the duration of HT, the better the sparing of brain tissue and the greater the effects on 
brain structure with increasing age 
21
 . 
In our study we found no association between HT use and dementia incidence over follow-up, 
which is in contrast with some
27-29
 but not all previous longitudinal studies
22, 30
. The WHIMS 
RCT also failed to find a significant association between dementia incidence and unopposed 
estrogen treatment
31
, although combined CEE+MPA was actually found to increase dementia 
risk
12
. The discrepancies between studies could results from differences in the age or health 
Ryan.  12 
 
status of the populations or the length of follow-up. HT may only be protective against AD when 
administered to younger women
22
. It is also possible that with a longer follow-up time for our 
study, and a higher number of incident dementia cases, we would have increased power to detect 
a significant association with HT.  
An interesting finding from our study was that HT may modify the association between Apoe-ε4 
and dementia, a possibility that has rarely been addressed previously. Women carrying the ε4 
allele are known to have an increased risk for dementia, and such a significant association was 
found in our study. However, among current HT users, the risk of dementia was not significantly 
increased for Apoe-ε4 positive women. This finding is supported by a recent study32, reporting 
that the 2-fold increased risk of familial AD associated with Apoe-ε4 was attenuated in women 
using HT. Experimental models have also shown that estradiol modulates Apoe expression. In a 
mouse memory model expressing human Apoe-ε4, which has reduced long-term potentiation 
(LTP) compared with wild-type mice, estradiol treatment selectively enhanced LTP 
33
. On the 
other hand, another study found that oral treatment was associated with a reduced risk of global 
cognitive dysfunction, but only in women without an Apoe-ε4 allele34. It has also being reported 
that Apoe-ε4 negative women using unopposed estrogen had better episodic learning and 
memory
35
, in unadjusted analysis. Surprisingly however, they found no difference in cognitive 
performance between Apoe-ε4 negative and positive non-HT users. Whether these different 
results are partly due to residual confounding remains uncertain, but these studies all highlight 
the importance of considering both HT and Apoe-ε4 status when examining cognition 
function/dementia. Importantly, the majority of previous studies on HT and the risk of incident 
dementia, including the WHIMS, did not control for Apoe-ε4 genotype. 
There are some limitations to our study. Data concerning HT use were gathered retrospectively 
and are subject to recall errors. Current HT users were however encouraged to present 
medications or prescriptions, so that treatment could be verified. The 4-year follow-up time may 
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have been insufficient to examine decline in cognition, particularly as there is a component of 
learning with repeat cognitive tasks. Likewise, with only 79 cases of incident dementia we had 
reduced statistical power to detect any associations with HT. Bias due to the exclusion of 
participants, including women with possible dementia at inclusion may have also reduced our 
power to detect significant associations if they were present. The strengths of our results relate to 
the design of the 3C study and its community-based population. In addition to dementia, a 
number of specific areas of cognitive function were examined and we were able to investigate 
particular characteristics associated with HT. The size of the dataset and the vast information 
relating to each participant enabled adjustment for an extensive range of covariates, which may 
confound the cognition-HT relationship, reducing the risk of prescription bias in regards to 
women using HT.  
While the association between HT and later-life cognition remains complex, our study suggests 
that HT is preferentially associated with certain cognitive domains and these associations vary 
depending on the duration ) and type of treatment used which might explain some discrepancies 
with previous RCTs, including  the WHIMS. We have no evidence that HT needs to be initiated 
close to the menopause to have a beneficial effect on later-life cognitive function. Our finding 
that HT can modify the association between Apoe-ε4 and dementia risk is potentially very 
interesting and thus warrants further investigation. Obviously recognised contraindications of HT 
use should be considered and HT prescription proceeded by a screening examination to 
determine probability of real benefit, rather than generalized prescription to all women.   
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Table 1. Cognitive functions which were assessed and participant’s baseline scores.   
Cognitive Test Domain  Range Median Score 
[Interquartile Range] 
    
Mini-Mental State Examination (MMSE) 
36
 Global Function 19 – 30 28    [26 - 29] 
Isaac’s Set Test (Isaacs) 37 Verbal Fluency 20 – 101 48    [42 – 55] 
Benton’s Visual Retention Test (BVRT) 38 Visual Memory 0 – 15 12    [10 – 13] 
Immediate and Delayed Recall (Word Recall) 39 Verbal Memory 1 – 10 9      [8 - 10] 
Trail Making test A (TMTA) 
40
 Psychomotor Speed 19 – 190 50    [40 – 63] 
Trail Making test B (TMTB) 
40
 Executive Function 30 - 379 96    [75 - 128] 
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Table 2.    Baseline socio-demographic, health and lifestyle characteristics of the 3130
a 
   participants, according to their use of hormone therapy (HT). 
Characteristic Never user 
(n=2169
a
) 
Past HT user 
(n=487
a
) 
Current HT 
user (n=474
a
) 
Test for difference 
Statistic        p   
 Mean (S.D.) ANOVA (df)  
Age 74.9 (5.3) 72.4 (4.7) 70.2 (3.3) 193.2 (2) <0.001   
Age at menopause 50.5 (4.1) 50.5 (4.3) 51.2 (4.2) 5.2 (2) 0.006   
Body mass index (BMI, kg/m²) 25.5 (4.4) 24.9 (3.8) 24.4 (3.4) 16.5 (2) <0.001   
 % 2 (df)  
≥ 12 years of education  24.1 26.1 35.0 24.0 (2) <0.001 
Married or has a partner 42.3 51.3 60.8 58.9 (2) <0.001 
High caffeine intake
b
 30.1 25.5 34.6 9.5 (2) 0.009 
Depressive symptoms (CESD≥16)c 27.2 30.0 28.1 1.6 (2) 0.46 
Carrier of the Apoe-ε4 allele 18.3 20.1 21.7 3.5 (2) 0.18 
Anticholinergic medication  8.9 7.4 8.9 1.2 (2) 0.54 
Comorbidity
d
 47.4 42.7 35.2 24.1 (2) <0.001 
Physical Incapacities
 e
 9.8 4.3 2.5 38.6 (2) <0.001 
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Centre
 f
      
               Bordeaux 19.6 13.6 13.3 23.9 (4) <0.001 
               Dijon 55.1 54.2 60.3   
               Montpellier 25.3 32.2 26.4   
      
MMSE score <26 15.3 15.8 12.9 2.1 (2) 0.35 
Isaacs set test score ≤40 24.1 20.3 12.0 33.8 (2) <0.001 
Benton score ≤10 32.0 25.9 19.2 34.1 (2) <0.001 
Word recall score ≤8 30.1 26.9 21.3 15.2 (2) <0.001 
Trail Making Task A score ≥69 21.5 16.2 10.8 29.0 (2) <0.001 
Trail Making Task B score ≥139 21.9 17.3 11.9 24.0 (2) <0.001 
 
a
Except for Trail Making Tasks A and B where N=2774 (1907 never users; 439 past HT users; 428 
current HT user). 
b 
Equivalent to three or more cups of coffee each day. 
c
The presence of depressive symptoms was assessed using the 20-item centre for epidemiology studies 
depression scale (CES-D), with a cut-off of ≥16. 
 
d
Participants were classified as having comorbidity if they had a history of vascular disease (angina 
pectoris, myocardial infarction, stroke, cardiovascular surgery, bradycardia or palpitations), other chronic 
illnesses (asthma, diabetes (fasting glucose≥7.0mmol/l or treatment), hypercholesterolemia (total 
cholesterol ≥6.2mmol/l), hypertension (resting blood pressure ≥160/95mm Hg or treatment) and thyroid 
problems) or a diagnoses of cancer within the last 2 years.  
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e
Participants were classified as disabled if they were unable to complete at least two tasks from either the 
Instrumental Activities of Daily Living or the Activities of Daily Living (ADL) scales. 
f
Percentages given within each treatment type.
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Table 3.  Logistic regression models for the association between HT and cognitive function.  
Use of Hormone 
Therapy 
 Global function, 
MMSE<26 
Verbal fluency, 
 Isaacs≤40 
Visual memory, 
BVRT ≤10 
Verbal memory, 
word recall ≤8 
 Psychomotor speed, 
TMTA ≥69 
Executive Function, 
TMTB≥139 
 N OR [95% CI] p OR [95% CI] p OR [95% CI] p OR [95% CI] p N OR [95% CI] p OR [95% CI] p 
UNADJUSTED               
Never  2169 1  1  1  1  1907 1  1  
Current  474 0.82 [0.61-1.10] 0.18 0.43 [0.32-0.58] 0.001 0.50 [0.39-0.64] 0.001 0.63 [0.50-0.80] 0.001 428 0.44 [0.32-0.61] 0.001 0.48 [0.35-0.66] 0.001 
Past: ≤2 years ago 141 1.19 [0.76-1.87] 0.44 0.52 [0.32-0.85] 0.008 0.73 [0.49-1.07] 0.11 0.89 [0.61-1.30] 0.55 129 0.84 [0.53-1.32] 0.44 0.81 [0.52-1.29] 0.38 
Past: >2 & ≤12yrs ago  140 1.15 [0.73-1.80] 0.56 0.86 [0.57-1.30] 0.48 0.76 [0.52-1.12] 0.17 0.53 [0.34-0.82] 0.004 127 0.49 [0.28-0.85] 0.01 0.70 [0.44-1.14] 0.16 
Past: >12 & ≤22yrs ago 116 0.82 [0.47-1.43] 0.49 0.87 [0.55-1.36] 0.54 0.68 [0.44-1.04] 0.08 0.97 [0.64-1.45] 0.87 104 0.66 [0.39-1.14] 0.14 0.60 [0.34-1.05] 0.07 
Past: >22yrs ago 90 0.93 [0.51-1.70] 0.82 1.15 [0.71-1.85] 0.57 0.82 [0.51-1.31] 0.40 1.28 [0.83-1.99] 0.27 79 0.93 [0.53-1.62] 0.79 0.91 [0.52-1.58] 0.73 
MULTIVARIATE
a
               
Never  2169 1  1  1  1  1907 1  1  
Current  474 1.02 [0.74-1.40] 0.90 0.64 [0.47-0.88] 0.005 0.70 [0.54-0.92] 0.009 0.89 [0.69-1.14] 0.35 428 0.66 [0.47-0.94] 0.02 0.79 [0.56-1.10] 0.16 
Past: ≤2 years ago 141 1.28 [0.81-2.04] 0.30 0.59 [0.36-0.98] 0.04 0.83 [0.56-1.25] 0.38 1.01 [0.68-1.49] 0.98 129 1.01 [0.63-1.62] 0.97 0.98 [0.61-1.59] 0.95 
Past: >2 & ≤12yrs ago  140 1.27 [0.78-2.04] 0.34 1.30 [0.83-2.01] 0.25 1.08 [0.72-1.62] 0.73 0.73 [0.46-1.44] 0.17 127 0.73 [0.42-1.29] 0.29 1.18 [0.71-1.95] 0.53 
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Past: >12 & ≤22yrs ago 116 0.85 [0.48-1.50] 0.58 1.06 [0.66-1.70] 0.80 0.79 [0.51-1.24] 0.32 1.17 [0.77-1.78] 0.46 104 0.87 [0.50-1.51] 0.61 0.78 [0.44-1.38] 0.39 
Past: >22yrs ago 90 0.98 [0.53-1.84] 0.96 1.14 [0.69-1.89] 0.60 0.82 [0.51-1.33] 0.42 1.24 [0.79-1.95] 0.34 79 0.90 [0.51-1.59] 0.71 0.90 [0.51-1.61] 0.73 
               
a
Adjusted for centre, age, education level, age at menopause, marital status, depressive symptoms, physical incapacities, comorbidity, Apoe-ε4 allele, high caffeine 
consumption, anticholinergic drugs and BMI.  
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Table 4.  Logistic regression models for the association between characteristics of current HT use and poor cognitive function at 
baseline. 
Characteristics of 
current HT users 
 Unadjusted 
Verbal fluency, 
Isaacs≤40 
Multivariate
a
 
Verbal fluency, 
 Isaacs≤40 
Unadjusted 
Visual memory, 
BVRT ≤10 
Multivariate
a
 
Visual memory, 
BVRT ≤10 
 Unadjusted 
Psychomotor speed, 
TMTA ≥69 
Multivariate
a
 
Psychomotor speed, 
TMTA ≥69 
 N OR [95% CI] p OR [95% CI] p OR [95% CI] p OR [95% CI] p N OR [95% CI] p OR [95% CI] p 
Duration of use:               
Never  used 2169 1  1  1  1  1907 1  1  
<10yrs  157 0.60 [0.39-0.93] 0.02 0.85 [0.53-1.35] 0.48 0.54 [0.36-0.81] <0.01 0.72 [0.47-1.09] 0.12 142 0.56 [0.34-0.93] 0.02 0.82 [0.49-1.38] 0.46 
>10 & ≤15yrs 160 0.40 [0.24-0.66] <0.01 0.71 [0.42-1.21] 0.21 0.45 [0.30-0.68] <0.01 0.71 [0.46-1.10] 0.12 143 0.46 [0.27-0.78] <0.01 0.81 [0.46-1.41] 0.45 
>15yrs 127 0.33 [0.18-0.60] <0.01 0.48 [0.26-0.90] 0.02 0.57 [0.37-0.88] <0.01 0.78 [0.50-1.23] 0.29 116 0.35 [0.18-0.67] <0.01 0.50 [0.26-0.98] 0.04 
Initiation of use:               
Never used 2169 1  1  1  1  1907 1  1  
≤5yrs of menopause  255 0.42 [0.28-0.62] <0.01 0.78 [0.51-1.19] 0.25 0.45 [0.33-0.64] <0.01 0.72 [0.51-1.03] 0.08 231 0.40 [0.26-0.63] <0.01 0.69 [0.43-1.10] 0.12 
>5yrs after menopause 194 0.47 [0.30-0.72] <0.01 0.58 [0.37-0.91] 0.02 0.60 [0.43-0.86] <0.01 0.72 [0.50-1.04] 0.08 175 0.53 [0.33-0.83] <0.01 0.72 [0.45-1.16] 0.18 
Type of HT:                
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Never used 2169 1  1  1  1  1907 1  1  
Estrogen alone 46 0.47 [0.20-1.12] 0.09 0.60 [0.25-1.46] 0.26 0.67 [0.34-1.32] 0.25 0.79 [0.39-1.61] 0.53 41 0.40 [0.14-1.11] 0.08 0.53 [0.18-1.52] 0.24 
Oral estrogen & 
progestagen 
78 0.52 [0.27-0.99] 0.05 0.85 [0.44-1.67] 0.64 0.46 [0.26-0.83] 0.01 0.69 [0.37-1.26] 0.23 73 0.39 [0.18-0.85] 0.02 0.58 [0.26-1.30] 0.19 
Transdermal estrogen & 
progestagen 
329 0.39 [0.27-0.56] <0.01 0.60 [0.41-0.88] 0.009 0.48 [0.36-0.67] <0.01 0.69 [0.50-0.94] 0.02 295 0.44 [0.30-0.65] <0.01 0.69 [0.46-1.03] 0.07 
    Natural progesterone   164 0.44 [0.27-0.71] <0.01 0.65 [0.39-1.07]  0.09    0.58 [0.39-0.85] <0.01 0.79 [0.53-1.19]    0.26    148 0.57 [0.35-0.93] 0.02 0.86 [0.52-1.42]    0.55 
    Synthetic progestin   165 0.34 [0.20-0.59] <0.01  0.55[0.32-0.95] 0.03 0.40 [0.26-0.61] <0.01  0.59[0.37-0.91]    0.02    147 0.33 [0.18-0.59] <0.01  0.52[0.28-0.97]    0.04 
Other / unsure 21 Nd  Nd  Nd  Nd  19   Nd  
a
Adjusted for centre, age, education level, age at menopause, marital status, depressive symptoms, physical incapacities, comorbidity, Apoe-ε4 allele, high caffeine 
consumption, anticholinergic drugs and BMI.  
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 Table 5. Cox proportional hazards models for the incidence of dementia and Alzheimer’s Disease according to HT use.  
Exposure  Incidence of Dementia  
(n=79 cases) 
 Incidence of Alzheimer’s Disease  
(n=53 cases)
b
 
 N Unadjusted 
HR [95% CI] 
 
p 
Multivariate 
HR [95% CI] 
 
p 
N Unadjusted 
HR [95% CI] 
 
p 
Multivariate 
HR [95% CI] 
 
p 
Never use of HT 2169 1  1  2146 1  1  
Past use of HT 487 0.76 (0.38-1.51) 0.43 0.74 (0.35-1.55) 0.42 485 0.79 (0.34-1.83) 0.57 0. 39 (0.39-2.23) 0.86 
Current use of HT 474 1.04 (0.43-2.50) 0.94 0.83 (0.32-2.17) 0.70 473 1.61 (0.60-4.32) 0.34 1.36 (0.44-4.20) 0.59 
           
Apoe-ε4 +  (all women) 3130 2.35 (1.53-3.60) <0.001 2.27 (1.48-3.49) <0.001 3104 2.38 (1.42-4.00) 0.001 2.21 (1.31-3.74) 0.003 
           
Apoe-ε4 - & never HT user  1773 1  1  1757 1  1  
Apoe-ε4 - & past HT user 389 0.61 (0.25-1.53) 0.30 0.54 (0.22-1.35) 0.19 387 0.56 (0.17-1.82) 0.34 0.48 (0.15-1.57) 0.23 
Apoe-ε4 - & current HT user 371 1.35 (0.52-3.53) 0.54 1.05 (0.41-2.73) 0.92 370 2.01 (0.67-5.97) 0.21 1.45 (0.49-4.32) 0.51 
Apoe-ε4 + & never HT user  396 2.33 (1.47-3.71) <0.001 2.24 (1.41-3.56) <0.001 389 2.29 (1.30-4.05) 0.004 2.13 (1.20-3.80) 0.01 
Apoe-ε4 + & past HT user 98 2.58 (0.92-7.23) 0.07 2.33 (0.83-6.53) 0.11 98 3.24 (0.98-10.7) 0.05 2.54 (0.76-8.53) 0.13 
Apoe-ε4 + & current HT user 103 1.13 (0.15-8.39) 0.91 0.87 (0.12-6.52) 0.89 103 2.17 (0.28-16.6) 0.46 1.47 (0.19-11.5) 0.71 
Ryan.  27 
 
a
Adjusted for age, education level, centre, high caffeine consumption, depressive symptoms, physical incapacities, comorbidity, marital status, anticholinergic 
drugs, body mass index and age at menopause (adjustment was also made for Apoe-ε4 when the association with HT use was examined).    
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